Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Angioblast Systems, Inc., a biotechnology company, engages in the development and commercialization of therapeutic products for the treatment of cardiovascular diseases. It provides adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, and DNAzymes, as well as MPC products for heart failure, heart attacks, peripheral artery diseases, and wound ulcers. The company has a strategic alliance with Mesoblast Limited. Angioblast Systems, Inc. was founded in 2001 and is headquartered in New York, New York.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

United States Surgical Corporation manufactures and markets wound closure products and advanced surgical devices. The company’s divisions include the Auto Suture, which offers surgical devices and laparoscopic instrumentation for general and specialty procedures; the Syneture Division that provides sutures and biosurgery products; and USS Sports Medicine, that offers spinal fixation and sports medicine products.

Part of Medtronic Plc, Covidien AG is a Swiss company located in Neuhausen am Rheinfall. The firm manufactures artificial teeth, dental metals, alloys, amalgams, and other equipment.

Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension. Its technology involves endovascular catheters to provide an efficacious, durable, cost-effective, and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Transverse Medical Inc. (TMI) has developed the *POINT-GUARD™ the only solution for complete cerebral embolic protection with dynamic double edge sealing. POINT-GUARD™ adapts and conforms to complex arch anatomy by maintaining contact with the aorta and addressing the unmet clinical need for maximum coverage of all great arch vessels to safeguard the patient’s brain from embolic debris (particles), which can result in a stroke during cardiovascular procedures, such as Transcatheter Aortic Valve Replacement (TAVR).

Medtronic Vascular designs and develops technologies for coronary, peripheral, and neurovascular indications. The company’s products include S7 Zipper MX Coronary Stent System, Clo-Sur PAD Nonwoven Hydrophilic Wound Dressing, Launcher Coronary Guide Catheter, and Stormer Over-the-Wire Balloon Dilatation Catheter. The company also offers Bridge Assurant Balloon-Expandable Stent Delivery System, GuardWire Plus Temporary Occlusion and Aspiration System, and S660 Coronary Stent. Medtronic Vascular was incorporated in 1991 and is based in Santa Rosa, California. As of January 29, 1999, Medtronic Vascular operates as a subsidiary of Medtronic.

Sherwood Services operates with a vision to provide "Total Facilities Care" in all commercial, health care, industrial, and educational facilities. Their exceptional cleaning services, professional staff, and customer-friendly scheduling make Sherwood a top janitorial and cleaning services provider.

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Westlake Village, California, the company was founded in February 1991. However, its present form is a result of a 2003 merger of three companies owned by Alfred E. Mann, Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing a allergy vaccine technology. MannKind Corporation was named after its founder, Alfred Mann. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

CryoLife, is a biological medical device company, which has been focused on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular reconstruction for patients for all ages. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using its SynerGraft technology. CryoLife's medical devices consist primarily of surgical adhesives, sealants, and hemostats, including BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), PerClot and HemoStase. In October of 2010, the Company began distributing PerClot for Starch Medical, Inc. (SMI). In May 2011, it acquired Cardiogenesis Corporation.

PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Stora Enso Oyj (Swedish: Stora [stuːra] and Finnish: Enso [enso]) is a manufacturer of pulp, paper and other forest products, headquartered in Helsinki, Finland. The majority of sales takes place in Europe, but there are also significant operations in Asia, South America and the United States. Stora Enso was formed in 1998, when the Swedish mining and forestry products company Stora AB merged with the Finnish forestry products company Enso Oyj. In 2018, the average number of employees was 26 000. For 2015, Stora Enso was ranked seventh in the world by sales and fourth by earnings, among forest, paper and packaging industry companies. For the first two quarters of 2018, the company was ranked second by net earnings among European forest and paper industry companies. The corporate history can be traced back to the oldest known preserved share certificate in the world, issued in 1288. Based on this, some observers consider Stora Enso to be the oldest limited liability company in the world.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

SCIMED Life Systems is a Manufacturing company.